Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06SOQ
|
|||
| Former ID |
DIB018809
|
|||
| Drug Name |
alpha5IA
|
|||
| Synonyms |
215874-86-5; 3-(5-Methylisoxazol-3-yl)-6-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy][1,2,4]triazolo[3,4-a]phthalazine; alpha5IA; UNII-1M7NI1A92L; 1M7NI1A92L; CHEMBL306422; L-822179; alpha-5IA; 3-(5-METHYLISOXAZOL-3-YL)-6-[(1-METHYL-1H-1,2,3-TRIAZOL-4-YL)METHOXY][1,2,4]TRIAZOLO[3,4-A]PHTHALAZI; 3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo[3,4-a]phthalazine; a5ia; alpha 5IA; 1,2,4-Triazolo[3,4-a]phthalazine, 3-(5-methyl-3-isoxazolyl)-6-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy]-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C17H14N8O2
|
|||
| Canonical SMILES |
CC1=CC(=NO1)C2=NN=C3N2N=C(C4=CC=CC=C43)OCC5=CN(N=N5)C
|
|||
| InChI |
1S/C17H14N8O2/c1-10-7-14(22-27-10)16-20-19-15-12-5-3-4-6-13(12)17(21-25(15)16)26-9-11-8-24(2)23-18-11/h3-8H,9H2,1-2H3
|
|||
| InChIKey |
NZMJFRXKGUCYNP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 215874-86-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
12015268, 14803522, 17194898, 43529821, 50076500, 50905383, 57371936, 103265126, 104033883, 114787994, 125330574, 128776961, 138607517, 144226094, 152043458, 162224548, 163642053, 178100918, 184528943, 185986642, 189293830, 198936893, 202823008, 223249279, 223394498, 223490451, 223746802, 227485990, 249816165, 251910595, 251966709, 252132264, 252268109
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor alpha-2 (GABRA2) | Target Info | Modulator (allosteric modulator) | [2] |
| GABA(A) receptor alpha-3 (GABRA3) | Target Info | Modulator (allosteric modulator) | [3] | |
| GABA(A) receptor alpha-5 (GABRA5) | Target Info | Modulator (allosteric modulator) | [4] | |
| GABA(A) receptor gamma-3 (GABRG3) | Target Info | Modulator (allosteric modulator) | [5] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Retrograde endocannabinoid signaling | ||||
| GABAergic synapse | ||||
| Morphine addiction | ||||
| Nicotine addiction | ||||
| Reactome | Ligand-gated ion channel transport | |||
| GABA A receptor activation | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| Iron uptake and transport | ||||
| SIDS Susceptibility Pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4095). | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). | |||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). | |||
| REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.